This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Micromedex® Mobile Drug Information App From Thomson Reuters Named One Of The 400 Essential Apps In The WIRED App Guide

Stocks in this article: TRI









ANN ARBOR, Mich., Dec. 14, 2011 /PRNewswire/ --  Micromedex®, the industry standard for clinical intelligence, was included in the first-ever WIRED App Guide to 400 Essential Apps in the "My Favorite Apps, The Physician" review section.

(Logo: http://photos.prnewswire.com/prnh/20090507/NY12658LOGO )

The publication, in an effort to provide mobile application users reviews of essential tools for every type of smartphone, boiled hundreds of thousands of available apps down to the 400 best.  Produced by the editors of WIRED magazine in collaboration with Gizmodo, the team tested and rated more than 400 apps for the first-ever WIRED App Guide. The special issue rates apps on the 10-point WIRED performance scale, noting 'WIRED' and 'TIRED' features, price and on which platforms each app is available.

The Micromedex® free Drug Information App which was named one of the year's 400 Essential Apps, contains drug information, including generic names, common trade names, adult and pediatric dosages, precautions, adverse effects, toxicology and more.

The review of the Micromedex® Drug Information App in the App Guide, written by Iltifat Husain, MD, highlighted its usability, stating: "Micromedex is a medical reference app that provides quick access to information for more than 4,500 search terms.  Its user interface is the best of all the prescription drug apps.  Many of the others have login menus or a bunch of clutter.  But Micromedex is so fast and easy."

The Micromedex Drug Information App was also recently selected to Apple's "Apps for Healthcare Professionals" category in iTunes. "This small and focused collection of apps helps customers discover and choose the best healthcare apps for iPhone & iPad," Afshad Mistri, Apple's Medical Market Manager for Worldwide Business Markets wrote in an email to developers reported in MobiHealthNews. Designed for both the iPhone and iPad, the Micromedex Drug Information App has received over 400 ratings in the Apple iTunes Store and has an average of 3.5 stars. 

Micromedex Drug Information App was also named to the Top 20 Free iPhone Medical Apps for Healthcare Professionals by the iMedicalAppsTeam.

"Micromedex® Mobile Apps were designed to provide fast and streamlined access to the industry's leading evidence-based clinical intelligence, when and where clinicians need it," said Thomas Hegelund, executive vice president at Thomson Reuters.  "As with any mobile application, ease-of-use and optimal performance is key for our users and we are thrilled at the response we have had with more than 600,000 downloads of the application from the Apple iTunes App Store."

Now available from the Apple iTunes App Store, in addition to the Micromedex Drug Information App, are the Micromedex Drug Interactions and Micromedex IV Compatibility Mobile Apps.  Micromedex Mobile Apps are free for Micromedex 2.0 subscribers. The WIRED App Guide is available on newsstands and as an app for iOS and Android smartphones.

About Thomson ReutersThomson Reuters is the world's leading source of intelligent information for businesses and professionals.  We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, healthcare and science and media markets, powered by the world's most trusted news organization.  With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs more than 55,000 people and operates in over 100 countries.  For more information, go to www.thomsonreuters.com.



1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,805.41 +127.51 0.76%
S&P 500 1,964.58 +13.76 0.71%
NASDAQ 4,483.7150 +30.9230 0.69%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs